According to filings with the U.S. Securities and Exchange Commission, Chai Discovery has raised $400 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite

About Chai Discovery
Chai Discovery is a San Francisco-based company that builds frontier artificial intelligence models and tools for predicting and reprogramming interactions between biochemical molecules. Its technology is aimed at helping scientists design new medicines on the computer and accelerate the discovery of breakthrough therapeutics. The company emphasizes de novo antibody and protein design, with a focus on moving beyond simply predicting binding toward creating candidates closer to real therapeutics. On its site, Chai highlights Chai-2 as a major step forward in de novo antibody design and says it is opening access to Chai-2 for commercial organizations. The company presents itself as part of the effort to transform biology from trial-and-error science into a more precise engineering discipline.

To learn more, visit https://www.chaidiscovery.com/
Linkedin: https://www.linkedin.com/company/chaidiscovery

Contact:
Joshua Meier, Chief Executive Officer
https://www.linkedin.com/in/joshua-meier-27a6861a

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.